It was only last October that UCB’s up-and-coming immunology powerhouse Bimzelx first crossed the FDA finish line in ...
After the unexpected success of their PHOENYCS GO study for dapirolizumab pegol in lupus earlier this fall, Biogen and UCB ...
A phase 3 trial of Biogen (NASDAQ:BIIB) and UCB's (OTCPK:UCBJF)(OTCPK:UCBJY) dapirolizumab pegol for systemic lupus ...
The board of United Community Banks, Inc. ( NYSE:UCB ) has announced that it will pay a dividend of $0.24 per share ...
UCB announced the FDA has approved BIMZELX for the treatment of adults with moderate-to-severe hidradenitis suppurativa. The approval ...
The novel IL-17A and IL-17F inhibitor has been approved for moderate to severe hidradenitis suppurativa, a chronic and ...
On Tuesday, UCB SA (OTC:UCBJY) (OTC:UCBJF) and Biogen Inc. (NASDAQ:BIIB) presented detailed results from the Phase 3 PHOENYCS ...
FDA approves UCB's Bimzelx for adults with moderate to severe hidradenitis suppurativa, supported by Phase 3 trials showing significant symptom improvement.
In a report released today, Charles Pitman CFA from Barclays maintained a Buy rating on UCB SA (0NZT – Research Report), with a price target of ...
The U.S. FDA added hidradenitis suppurativa to the label for UCB SA’s Bimzelx (bimekizumab-bkzx), throwing renewed light on the indication, a chronic disease that causes painful, boil-like lumps that ...
A phase 3 trial of Biogen (NASDAQ:BIIB) and UCB's (OTCPK:UCBJF)(OTCPK:UCBJY) dapirolizumab pegol for systemic lupus erythematosus met its primary endpoint, demonstrating significant improvement in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback